Health & Fitness
Health and Fitness
Health and Fitness
Fri, February 10, 2012
Thu, February 9, 2012
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference -- RICHMOND, Calif., Feb. 9, 2012 /PRNewswire/ --
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference
RICHMOND, Calif., Feb. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: [ SGMO ]) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:30 pm ET on Thursday, February 16, 2012, at the 2012 Leerink Swann Global Healthcare Conference which will be held in New York City.
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section [ http://investor.sangamo.com/index.cfm ] under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. Sangamo has a Phase 2 clinical trial and two Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies, and Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) for gene regulation. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at [ www.sangamo.com ].
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.
[ Back to top ] RELATED LINKS
[ http://www.sangamo.com ]
